PRADA: Prevalence of Anal Sphincter Defects After Childbirth

Sponsor
Universidad de Zaragoza (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05196620
Collaborator
Hospital Clínico Universitario Lozano Blesa (Other), Instituto de Investigación Sanitaria Aragón (Other)
100
1
32
3.1

Study Details

Study Description

Brief Summary

The incidence of obstetric sphincter tears has risen to 15-30% and the prevalence of anal incontinence (AI) symptoms after childbirth may be as high as 40%. The present study aims to evaluate the prevalence of anal sphincter defects after childbirth in primiparous women-

Condition or Disease Intervention/Treatment Phase
  • Other: Endoanal Ultrasound (EAUS)

Detailed Description

The incidence of sphincter defect in women has raised in recently with current rates as high as 30% after vaginal deliveries. Fecal incontinence could be present at the time of the delivery but it is a real problem longtime after, in women older than 60 years.

It is of great importance not only an early detection but to indicates the best possible management as soon as posible.

The design is a prospective observational study including primiparous woman, without previous anal surgery.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Prevalence of Anal Sphincter Defects After Childbirth in Primiparous Women
Anticipated Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
EAUS

Patients with EAUS pre and postpartum

Other: Endoanal Ultrasound (EAUS)
Endoanal Ultrasound pre- and postpartum

Outcome Measures

Primary Outcome Measures

  1. Integrity of anal sphincter [4 months]

    No defect detected on EAUS

  2. Defects on anal canal [4 months]

    Disruption of any of the anal canal sphincters

Secondary Outcome Measures

  1. QoL [4 months]

    According to a dedicated questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Primiparous pregnant patients aged >18 y, evaluated during pregnancy and after childbirth, including both vaginal and cesarean deliveries.
Exclusion Criteria:
  • Non primiparous patients and patients with a history of anal surgery

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Clinico Lozano Blesa Zaragoza Spain 50009

Sponsors and Collaborators

  • Universidad de Zaragoza
  • Hospital Clínico Universitario Lozano Blesa
  • Instituto de Investigación Sanitaria Aragón

Investigators

  • Principal Investigator: Jose-M Ramirez, Prof, Universidad de Zaragoza

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jose-M Ramirez, Prof, Universidad de Zaragoza
ClinicalTrials.gov Identifier:
NCT05196620
Other Study ID Numbers:
  • UZaragoza-3
First Posted:
Jan 19, 2022
Last Update Posted:
Jan 19, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jose-M Ramirez, Prof, Universidad de Zaragoza
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 19, 2022